Comparative Pharmacology
Head-to-head clinical analysis: KERYDIN versus MONISTAT 7 COMBINATION PACK.
Peer-Reviewed Evidence
Head-to-head clinical analysis: KERYDIN versus MONISTAT 7 COMBINATION PACK.
KERYDIN vs MONISTAT 7 COMBINATION PACK
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
KERYDIN (tavaborole) is a boron-based antifungal that inhibits fungal protein synthesis by blocking the activity of leucyl-tRNA synthetase, thereby preventing aminoacylation of tRNA(Leu) and impairing protein synthesis in dermatophytes.
Miconazole, an imidazole antifungal, inhibits fungal cytochrome P450 14α-demethylase, preventing conversion of lanosterol to ergosterol, thereby disrupting fungal cell membrane synthesis.
8 mg/kg (max 800 mg) IV over 2 hours once daily for 14 days
Intravaginal: one applicatorful (200 mg miconazole nitrate) at bedtime for 7 nights. Also: topical cream (2%) applied to affected area twice daily for 7 days.
None Documented
None Documented
Terminal elimination half-life is approximately 24 hours, supporting once-daily topical application.
Terminal elimination half-life is approximately 24 hours for miconazole after systemic absorption, reflecting slow tissue redistribution and hepatic clearance. After intravaginal administration, systemic absorption is minimal (<1.4%), so half-life is not clinically relevant.
Primarily hepatic metabolism; renal excretion of metabolites accounts for approximately 88% of the dose, with negligible fecal excretion (<1% as unchanged drug).
Miconazole is primarily metabolized in the liver; less than 1% of absorbed dose is excreted unchanged in urine. Fecal excretion accounts for approximately 50% of the dose, primarily as metabolites. Biliary excretion is minimal.
Category C
Category C
Antifungal
Antifungal